Mutational status of EGFR and KIT in thymoma and thymic carcinoma

Lung Cancer

Volumn 62, Issue 3, 2008, Pages 316-320

  Yoh, Kiyotaka ^a   Nishiwaki, Yutaka ^a   Ishii, Genichiro ^a   Goto, Koichi ^a   Kubota, Kaoru ^a   Ohmatsu, Hironobu ^a   Niho, Seiji ^a   Nagai, Kanji ^a   Saijo, Nagahiro ^a  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

EGFR; KIT; Mutation; Thymic carcinoma; Thymoma; Treatment

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PARAFFIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DNA ISOLATION; EXON; FEMALE; GENE MUTATION; GENOMICS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MISSENSE MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; THYMOMA; THYMUS CANCER;

ADULT; AGED; DNA MUTATIONAL ANALYSIS; EXONS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; MUTATION, MISSENSE; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTOR, EPIDERMAL GROWTH FACTOR; THYMOMA; THYMUS NEOPLASMS;

EID: 56949104588     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2008.03.013     Document Type: Article

References (22)

1. Strobel P., Marx A., Zettl A., and Muller-Hermelink H.K. Thymoma and thymic carcinoma: an update of the WHO Classification 2004. Surg Today 35 (2005) 805-811
2. Strobel P., Bauer A., Puppe B., Kraushaar T., Krein A., Toyka K., et al. Tumor recurrence and survival in patients treated for thymomas and thymic squamous cell carcinomas: a retrospective analysis. J Clin Oncol 22 (2004) 1501-1509
3. Eng T.Y., Fuller C.D., Jagirdar J., Bains Y., and Thomas Jr. C.R. Thymic carcinoma: state of the art review. Int J Radiat Oncol Biol Phys 59 (2004) 654-664
4. Kondo K., and Monden Y. Therapy for thymic epithelial tumors: a clinical study of 1320 patients from Japan. Ann Thorac Surg 76 (2003) 878-884
5. Thomas C.R., Wright C.D., and Loehrer P.J. Thymoma: state of the art. J Clin Oncol 17 (1999) 2280-2289
6. Hynes N.E., and Lane H.A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5 (2005) 341-354
7. Salomon D.S., Brandt R., Ciardiello F., and Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19 (1995) 183-232
8. Heinrich M.C., Blanke C.D., Druker B.J., and Corless C.L. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 20 (2002) 1692-1703
9. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350 (2004) 2129-2139
10. Heinrich M.C., Corless C.L., Demetri G.D., Blanke C.D., von Mehren M., Joensuu H., et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21 (2003) 4342-4349
11. Henley J.D., Cummings O.W., and Loehrer Sr. P.J. Tyrosine kinase receptor expression in thymomas. J Cancer Res Clin Oncol 130 (2004) 222-224
12. Ionescu D.N., Sasatomi E., Cieply K., Nola M., and Dacic S. Protein expression and gene amplification of epidermal growth factor receptor in thymomas. Cancer 103 (2005) 630-636
13. Pan C.C., Chen P.C., and Chiang H. KIT (CD117) is frequently overexpressed in thymic carcinomas but is absent in thymomas. J Pathol 202 (2004) 375-381
14. Nakagawa K., Matsuno Y., Kunitoh H., Maeshima A., Asamura H., and Tsuchiya R. Immunohistochemical KIT (CD117) expression in thymic epithelial tumors. Chest 128 (2005) 140-144
15. Strobel P., Hartmann M., Jakob A., Mikesch K., Brink I., Dirnhofer S., et al. Thymic carcinoma with overexpression of mutated KIT and the response to imatinib. N Engl J Med 350 (2004) 2625-2626
16. Yamaguchi H., Soda H., Kitazaki T., Tsukamoto K., Hayashi T., and Kohno S. Thymic carcinoma with epidermal growth factor receptor gene mutations. Lung Cancer 52 (2006) 261-262
17. Masaoka A., Monden Y., Nakahara K., and Tanioka T. Follow-up study of thymomas with special reference to their clinical stages. Cancer 48 (1981) 2485-2492
18. Tarn C., Merkel E., Canutescu A.A., Shen W., Skorobogatko Y., Heslin M.J., et al. Analysis of KIT mutations in sporadic and familial gastrointestinal stromal tumors: therapeutic implications through protein modeling. Clin Cancer Res 11 (2005) 3668-3677
19. Suzuki E., Sasaki H., Kawano O., Endo K., Haneda H., Yukiue H., et al. Expression and mutation statuses of epidermal growth factor receptor in thymic epithelial tumors. Jpn J Clin Oncol 36 (2006) 351-356
20. Meister M., Schirmacher P., Dienemann H., Mechtersheimer G., Schnabel P.A., Kern M.A., et al. Mutational status of the epidermal growth factor receptor (EGFR) gene in thymomas and thymic carcinomas. Cancer Lett 248 (2007) 186-191
21. Chou T.Y., Chiu C.H., Li L.H., Hsiao C.Y., Tzen C.Y., Chang K.T., et al. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. Clin Cancer Res 11 (2005) 3750-3757
22. Corless C.L., Fletcher J.A., and Heinrich M.C. Biology of gastrointestinal stromal tumors. J Clin Oncol 22 (2004) 3813-3825